Lymphoma, T-Cell
Showing 1 - 25 of >10,000
T-Cell Lymphoma Trial (Brentuximab vedotin)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- (no location specified)
Jun 30, 2022
NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))
Not yet recruiting
- NK/T-cell Lymphoma
- Positron Emission Tomography/Magnetic Resonance (PET/MR)
-
Shanghai, Shanghai, ChinaRuijin Hospital
Dec 14, 2022
Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CHOP+selinexor+5-Azacitidine
- +2 more
- (no location specified)
Dec 29, 2022
Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)
Not yet recruiting
- Extranodal NK/T-cell Lymphoma
- Sugemalimab
- +4 more
- (no location specified)
Jan 17, 2023
Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,
Recruiting
- Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Chidamide combined with CHOP
- Chidamide
-
Guangzhou, Guangdong, ChinaSun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022
T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- Pembrolizumab
- (no location specified)
Jul 22, 2022
NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)
Not yet recruiting
- NK/T Cell Lymphoma
- +2 more
-
Guangzhou, Guangdong, China
- +1 more
Jan 12, 2023
T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- CD7 CAR-T cells
-
Shenzhen, Guangdong, ChinaLi Yu
Nov 11, 2022
Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)
Recruiting
- Peripheral T Cell Lymphoma
- Azacitidine Injection
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022
Peripheral T-cell Lymphoma Trial in Tianjin (Lposomal mitoxantrone HCl,Cyclophosphamide,Vincristine,Etoposide and
Not yet recruiting
- Peripheral T-cell Lymphoma
- Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jul 13, 2022
T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)
Not yet recruiting
- T Cell Lymphoma
- Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
- (no location specified)
Mar 6, 2023
Tissue Repository: CTCL Collection Protocol
Recruiting
- Lymphoma, T-Cell, Cutaneous
- +2 more
-
New York, New YorkColumbia University Medical Center
May 2, 2022
Cutaneous T-Cell Lymphoma/Mycosis Fungoides Trial in Fairport (Hypericin)
Active, not recruiting
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
-
Fairport, New YorkRochester Skin Lymphoma Medical Group
Jun 28, 2022
Cutaneous T Cell Lymphoma Trial in Chicago (APR-TD011 (RLF-TD011))
Not yet recruiting
- Cutaneous T Cell Lymphoma
- APR-TD011 (RLF-TD011)
-
Chicago, IllinoisDermatology CTU
Feb 6, 2023
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by
Not yet recruiting
- Adult T-cell Leukemia/Lymphoma
- +4 more
- CC-486 (5-azacitidine)
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride
Not yet recruiting
- NK-T-Cell Lymphoma, Extranodal
- Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
- (no location specified)
Mar 7, 2023
T-cell Lymphoma, Virus, Intravenous Injection Trial (Oncolytic Virus Injection(RT-01))
Not yet recruiting
- T-cell Lymphoma
- +2 more
- Oncolytic Virus Injection(RT-01)
- (no location specified)
May 18, 2022
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory Trial in United States (LB1901)
Active, not recruiting
- T-Cell Lymphoma
- +4 more
- LB1901
-
Rochester, Minnesota
- +3 more
Feb 15, 2022
Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)
Recruiting
- Peripheral T Cell Lymphoma
- Mitoxantrone liposome、Chidamide、Azacitidine
-
Zhejiang, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 9, 2022
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
May 3, 2022
Lymphoma, T-Cell Trial in Yanda (Senl-T7)
Recruiting
- Lymphoma, T-Cell
- Senl-T7
-
Yanda, Hebei, ChinaHebei yanda Ludaopei Hospital
May 24, 2022
T Cell Lymphoma Trial in Seoul (ACHOP)
Not yet recruiting
- T Cell Lymphoma
-
Seoul, Korea, Republic of81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Apr 18, 2022
T-cell Non-Hodgkin's Lymphoma Trial (CD147- CAR T cells)
Not yet recruiting
- T-cell Non-Hodgkin's Lymphoma
- CD147- CAR T cells
- (no location specified)
Aug 1, 2022
Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)
Enrolling by invitation
- Peripheral T-cell Lymphoma Targeted Therapy
- Azacitidine
- +5 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023